Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trichomonas vaginalis | Clan AD, family A22, presenilin-like aspartic peptidase | 0.1706 | 0.2001 | 1 |
Brugia malayi | Presenilin family protein | 0.1706 | 0.2001 | 0.2001 |
Trichomonas vaginalis | Clan AD, family A22, presenilin-like aspartic peptidase | 0.1706 | 0.2001 | 1 |
Loa Loa (eye worm) | gamma-secretase subunit pen-2 | 0.1601 | 0.1812 | 0.1812 |
Schistosoma mansoni | subfamily A22A unassigned peptidase (A22 family) | 0.1706 | 0.2001 | 0.1648 |
Trypanosoma brucei | Aph-1 protein, putative | 0.2391 | 0.3238 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0832 | 0.0423 | 0.0423 |
Brugia malayi | hypothetical protein | 0.0832 | 0.0423 | 0.0423 |
Schistosoma mansoni | gamma-secretase subunit aph-1 | 0.6137 | 1 | 1 |
Echinococcus multilocularis | gamma secretase subunit aph 1 | 0.6137 | 1 | 1 |
Trichomonas vaginalis | Clan AD, family A22, presenilin-like aspartic peptidase | 0.1706 | 0.2001 | 1 |
Brugia malayi | gamma-secretase subunit pen-2 | 0.1601 | 0.1812 | 0.1812 |
Loa Loa (eye worm) | gamma-secretase subunit aph-1 | 0.6137 | 1 | 1 |
Trypanosoma cruzi | Aph-1 protein, putative | 0.2391 | 0.3238 | 1 |
Echinococcus multilocularis | presenilin | 0.1706 | 0.2001 | 0.1648 |
Echinococcus granulosus | gamma secretase subunit aph 1 | 0.6137 | 1 | 1 |
Leishmania major | presenilin-like aspartic peptidase, putative,presenilin-like aspartic peptidase, clan AD, family A22A, putative | 0.1706 | 0.2001 | 0.5 |
Entamoeba histolytica | presenilin 1 peptidase, putative | 0.1706 | 0.2001 | 0.5 |
Brugia malayi | hypothetical protein | 0.0832 | 0.0423 | 0.0423 |
Trypanosoma cruzi | Aph-1 protein, putative | 0.2391 | 0.3238 | 1 |
Toxoplasma gondii | hypothetical protein | 0.0598 | 0 | 0.5 |
Echinococcus multilocularis | presenilin enhancer 2 | 0.1601 | 0.1812 | 0.1451 |
Echinococcus granulosus | presenilin | 0.1706 | 0.2001 | 0.1648 |
Echinococcus granulosus | presenilin enhancer 2 | 0.1601 | 0.1812 | 0.1451 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.